Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease

Neurotoxicity Research

Volumn 5, Issue 5, 2003, Pages 307-313

  Andersen, Julie K ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; HERBICIDE; IRON; NERVE PROTEIN; PARAQUAT; SYNUCLEIN;

CHEMICALLY INDUCED DISORDER; DRUG POTENTIATION; HUMAN; METABOLISM; NERVE DEGENERATION; PARKINSON DISEASE; PHYSIOLOGY; POLLUTANT; REVIEW; RISK FACTOR;

DOPAMINE; DRUG SYNERGISM; ENVIRONMENTAL POLLUTANTS; HERBICIDES; HUMANS; IRON; NERVE DEGENERATION; NERVE TISSUE PROTEINS; PARAQUAT; PARKINSON DISEASE, SECONDARY; RISK FACTORS; SYNUCLEINS;

EID: 1242264027     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033150     Document Type: Article

References (87)

1. Anderson, C, H Checkoway, GM Franklin, S Beresford, T Smith-Weller and PD Swanson (1999) Dietary factors in Parkinson's disease: The role of food groups and specific foods. Mov. Disord. 14, 21-27.
2. Aoki S, Y Okada, K Nishimura, AJ Barkovich, BO Kjos, RC Brasch and D Norman (1989) Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T. Radiology 172, 381-385.
3. Baba M, S Nakajo, PH Tu, T Tomita, K Nakaya, VM Lee, JQ Trojanowski and T Iwatsubo (1998) Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879-884.
4. Beal MF (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31, 119-130.
5. Ben-Shachar D and MB Youdim (1993) Iron, melanin and dopamine interaction: Relevance to Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 17, 139-150.
6. Brooks AI, CA Chadwick, HA Gelbard, DA Cory-Slechta and HJ Federoff (1999) Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res. 823, 1-10.
7. bin/cas/tree/store/bres/cas_sub/browese/browse.cgi?year=1999&volume= 1823&issue=1991-1992&aid=15178.
8. Burkitt MJ, MB Kadiiska, PM Hanna, SJ Jordan and RP Mason (1993) Electron spin resonance spin-trapping investigation into the effects of paraquat and desferrioxamine on hydroxyl radical generation during acute iron poisoning. Mol. Pharmacol. 43, 257-263.
9. Bus JS and JE Gibson (1984) Paraquat: Model for oxidant-initiated toxicity. Environ. Health Perspect. 55, 37-46.
10. Castellani RJ, SL Siedlak, G Perry and MA Smith (2000) Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol. (Berl.) 100, 111-114.
11. Chun HS, GE Gibson, LA DeGiorgio, H Zhang, VJ Kidd and JH Son (2001) Dopaminergic cell death induced by MPP(+), oxidant and specific neurotoxicants shares the common molecular mechanism. J. Neurochem. 76, 1010-1021.
12. Clejan L and AI Cederbaum (1989) Synergistic interactions between NADPH-cytochrome P-450 reductase, paraquat, and iron in the generation of active oxygen radicals. Biochem. Pharmacol. 38, 1779-1786.
13. Corasaniti MT, MC Strongoli, D Rotiroti, G Bagetta and G Nistico (1998) Paraquat: A useful tool for the in vivo study of mechanisms of neuronal cell death. Pharmacol. Toxicol. 83, 1-7.
14. D'Amato RJ, GM Alexander, RJ Schwartzman, CA Kitt, DL Price and SH Snyder (1987) Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature 327, 324-326.
15. Dexter DT, CJ Carter, FR Wells, F Javoy-Agid, Y Agid, A Lees, P Jenner and CD Marsden (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52, 381-389.
16. Dexter DT, A Carayon, M Vidailhet, M Ruberg, F Agid, Y Agid, AJ Lees, FR Wells, P Jenner and CD Marsden (1990) Decreased ferritia levels in brain in Parkinson's disease. J. Neurochem. 55, 16-20.
17. Duda JE, VM Lee and JQ Trajanowski (2000) Neuropathology of synuclein aggregates. J. Neurosci. Res. 61, 121-127.
18. Fahn S and G Cohen (1992) The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it. Ann. Neurol. 32, 804-812.
19. Feany MB and WW Bender (2000) A Drosophila model of Parkinson's disease. Nature 404, 394-398.
20. Fredriksson A, M Fredriksson and P Eriksson (1993) Neonatal exposure to paraquat or MPTP induces permanent changes in striatum dopamine and behavior in adult mice. Toxicol. Appl. Pharmacol. 122, 258-264.
21. Gerlach M, H Desser, MB Youdim and P Riederer (1996) New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. J. Neural Transm. Suppl. 48, 7-21.
22. Giasson BL, R Jakes, M Goedert, JE Duda, S Leight, JQ Trojanowski and VM Lee (2000) A panel of epitope-specific antibodies detects protein domains distributed throughout human α-synuclein in Lewy bodies of Parkinson's disease. J. Neurosci. Res. 59, 528-533.
23. Gorell JM, BA Rybicki, C Cole Johnson and EL Peterson (1999) Occupational metal exposures and the risk of Parkinson's disease. Neuroepidemiology 18, 303-308.
24. Gorell IM, CC Johnson, BA Rybicki, EL Peterson and RJ Richardson (1998) The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50, 1346-1350.
25. Gutteridge JM (1992) Iron and oxygen radicals in brain. Ann. Neurol. 32(Suppl.), S16-S21.
26. Hashimoto M, A Takeda, LJ Hsu, T Takenouchi and E Masliah (1999) Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease. J. Biol. Chem. 274, 28849-28852.
27. Hashimoto M, LJ Hsu, E Rockestein, T Takenouchi, M Mallory and E Masliah (2002) α-Synuclein protects against oxidative stress via inactivation of the c-jun N-terminal kinase stress signaling pathway in neuronal cells. J. Biol. Chem. 14, 14.
28. Hertzman C, M Wiens, D Bowering, B Snow and D Calne (1990) Parkinson's disease: A case-control study of occupational and environmental risk factors. Am. J. Ind. Med. 17 349-355.
29. Hirsch EC (1992) Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? Ann. Neurol. 32, S88-S93.
30. Hirsch EC, AM Graybiel and Y Agid (1989) Selective vulnerability of pigmented dopaminergic neurons in Parkinson's disease. Acta Neurol. Scand. Suppl. 126, 19-22.
31. Hsu LJ, Y Sagara, A Arroyo, E Rockenstein, A Sisk, M Mallory, J Wong, T Takenouchi, M Hashimoto and E Masliah (2000) α-Synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157, 401-410.
32. Hubble JP, T Cao, RE Hassanein, JS Neuberger and WC Koller (1993) Risk factors for Parkinson's disease. Neurology 43, 1693-1697.
33. Imaizumi Y (1995) Geographical variations in mortality from Parkinson's disease in Japan, 1977-1985. Acta Neurol. Scand. 91, 311-316.
34. Jellinger KA, E Kienzl, G Rumpelmaier, W, Paulus, P Riederer, H Stachelberger, MB Youdim and D Ben-Shachar (1993) Iron and ferritin in substantia nigra in Parkinson's disease. Adv. Neurol. 60, 267-272.
35. Jenner P (1993) Altered mitochondrial function, iron metabolism and glutathone levels in Parkinson's disease. Acta Neurol. Scand. Suppl. 146, 6-13.
36. Jenner P and CW Olanow (1998) Understanding cell death in Parkinson's disease. Ann. Neurol. 44, S72-S84.
37. Jha N, MJ Kumar, R Boonplueang and JK Andersen (2002) Glutathione decreases in dopaminergic PC12 cells interfere with the ubiquitin protein degradation pathway: Relevance for Parkinson's disease? J. Neurochem. 80, 555-561.
38. Jimenez-Jimenez FJ, D Mateo and S Gimenez-Roldan (1992) Exposure to well water and pesticides in Parkinson's disease: A case-control study in the Madrid area. Mov. Disord. 7, 149-152.
39. Junn E and MM Mouradian (2002) Human α-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 320, 146-150.
40. Kadiiska MB, PM Hanna and RP Mason (1993) In vivo ESR spin trapping evidence for hydroxyl radical-mediated toxicity of paraquat and copper in rats. Toxicol. Appl. Pharmacol. 123, 187-192.
41. Kaur D, F Yantiri, S Rajagopalan, J Kumar, JQ Mo, R Boonplueang, D Viswanath, R Jacobs, L Yang, MF Beal, D DiMonte, I Volitaskis, L Ellerby, RA Cherny, AI Bush and JK Andersen (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo. A novel therapy for Parkinson's disease. Neuron 37, 899-909.
42. Koller WC (1986) Paraquat and Parkinson's disease. Neurology 36, 1147.
43. Kruger R, W Kuhn, T Muller, D Woitalla, M Graeber, S Kosel, H Przuntek, JT Epplen, L Schols and O Riess (1998) Ala 30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nature Genet. 18, 106-108.
44. Lan J and DH Jiang (1997a) Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural Transm. 104, 469-481.
45. Lan J and DH Jiang (1997b) Excessive iron accumulation in the brain: A possible potential risk of neurodegeneration in Parkinson's disease. J. Neural Transm. 104, 649-660.
46. Langston JW, P Ballard, JW Tetrud and I Irwin (1983) Chronic Parkinsonism in humans due to a product of meperidine analog synthesis. Science 219, 979-980.
47. Lanska DJ (1997) The geographic distribution of Parkinson's disease mortality in the United States. J. Neurol. Sci. 150, 63-70.
48. Lee M, D Hyun, B Halliwell and P Jenner (2001) Effect of the overexpression of wild-type or mutant α-synuclein or cell susceptibility to insult. J. Neurochem. 76, 998-1009.
49. Liou HH, RC Chen, YF Tsai, WP Chen, YC Chang and MC Tsai (1996) Effects of paraquat on the substantia nigra of the wistar rats: Neurochemical, histological, and behavioral studies. Toxicol. Appl. Pharmacol. 137, 34-41.
50. Liou HH, MC Tsai, CJ Chen, JS Jeng, YC Chang, SY Chen and RC Chen (1997) Environmental risk factors and Parkinson's disease: A case-control study in Taiwan. Neurology 48, 1583-1588.
51. Liou HH, RC Chen, TH Chen, YF Tsai and MC Tsai (2001) Attenuation of paraquat-induced dopaminergic toxicity on the substantia migra by (-)-deprenyl in vivo. Toxicol. Appl. Pharmacol. 172, 37-43.
52. Logroscino G, K Marder, J Graziano, G Freyer, V Slavkovich, N Lojacono, L Cote and R Mayeux (1998) Dietary iron, animal fats, and risk of Parkinson's disease. Mov. Disord. 13, 13-16.
53. Manning-Bog AB, AL McCormack, J Li, VN Uversky, AL Fink and D Di Monte (2002) The herbicide paraquat causes up-regulation and aggregation of α-synuclein in mice: Paraquat and α-synuclein. J. Biol. Chem. 277, 1641-1644.
54. Masliah E, E Rockenstein, I Veinbergs, M Mallory, M Hashimoto, A Takeda, Y Sagara, A Sisk and L Mucke (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders. Science 287, 1265-1269.
55. McCormack AL and D Di Monte (2003) Effects of l-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J. Neurochem. 85, 82-86.
56. McCormack AL, M Thiruchelvam, AB Manning-Bog, C Thiffault, JW Langston, DA Cory-Slechta and DA DiMonte (2002) Environmental risk factors and Parkinson's disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 10(2), 119-127.
57. Munch G, HJ Luth, A Wong, T Arendt, E Hirsch, R Ravid and P Riederer (2000) Crosslinking of α-synuclein by advanced glycation endproducts - an early pathophysiological step in Lewy body formation? J. Chem. Neuroanat. 20, 253-257.
58. Ostrerova-Golts N, L Petrucelli, J Hardy, JM Lee, M Farer and B Wolozin (2000) The A53T α-synuclein mutation increases irondependent aggregation and toxicity. J. Neurosci. 20, 6048-6054.
59. Paik SR, HJ Shin, JH Lee, CS Chang and J Kim (1999) Copper(II)-induced self-oligomerization of α-synuclein. Biochem. J. 340, 821-828.
60. Perry TL and VW Yong (1986) Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67, 269-274.
61. Perry TL, DV Godin and S Hansen (1982) Parkinson's disease: A disorder due to nigral glutathione deficiency? Neurosci. Lett. 33, 305-310.
62. Perry TL, VW Yong, RA Wall and K Jones (1986) Paraquat and two endogenous analogues of the neurotoxic substance N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to not damage dopaminergic nigrostriatal neurons in the mouse. Neurosci. Lett. 69, 285-289.
63. Poirier J, J Donaldson and A Barbeau (1985) The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals. Biochem. Biophys. Res. Commun. 128, 25-33.
64. Polymeropoulos MH, C Lavedan, E Leroy, SE Ide, A Dehejia, A Dutra B Pike, H Root, J Rubenstein, R Boyer, ES Stenroos, S Chandrasekharappa, A Athanassiadou, T Papapetropoulos, WG Johnson, AM Lazzarini, RC Duvoisin, G Di Iorio, LI Golbe and RL Nussbaum (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
65. Przedborski S, V Jackson-Lewis, AB Naini, M Jakowec, G Petzinger, R Miller and M Akram (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A technical review of its utility and safety. J. Neurochem. 76, 1265-1274.
66. Riederer P, E Sofic, WD Rausch, B Schmidt, GP Reynolds, K Jellinger and MB Youdim (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520.
67. Schneider JS and FJ Denaro (1988) Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain. J. Neuropathol. Exp. Neurol. 47, 452-458.
68. Semchuk KM, EJ Love and RG Lee (1992) Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 42, 1328-1335.
69. Shimada H, K Hirai, E Simamura and J Pan (1998) Mitochondrial NADH-quinone oxidoreductase of the outer membrane is responsible for paraquat cytotoxicity in rat livers. Arch. Biochem. Biophys. 351, 75-81.
70. Shimizu K, K Ohtaki, K Matsubara, K Aoyama, T Uezono, O Saito, M Suno, K Ogawa, N Hayase, K Kimura and H Shiono (2001) Carrier mediated processes in blood-brain barrier penetration and neural uptake of paraquat. Brain Res. 906, 135-142
71. Sofic E, W Paulus, K Jellinger, P Riederer and MB Youdim (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56, 978-982.
72. Spillantini MG, ML Schmidt, VM Lee, JQ Trojanowski, R Jakes and M Goedert (1997) α-Synuclein in Lewy bodies. Nature 388, 839-840.
73. Spillantini MG, RA Crowther, R Jakes, M Hasegawa and M Goedert (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469-6473.
74. Stephenson J (2000) Exposure to home pesticides linked to Parkinson disease. JAMA 283, 3055-3056.
75. Tanner CM, R Ottman, SM Goldman, J Ellenberg, P Chan, R Mayeux and JW Langston (1999) Parkinson disease in twins: An etiologic study. JAMA 281, 341-346.
76. Taylor EM and EH Morgan (1990) Developmental changes in transferrin and iron uptake by the brain in the rat. Brain Res. Dev. Brain Res. 55, 35-42.
77. Taylor EM, A Crowe and EH Morgan (1991) Transferrin and iron uptake by the brain: Effects of altered iron status. J. Neurochem. 57, 1584-1592.
78. Thiruchelvam M, BJ Brockel, EK Richfield, RB Baggs and DA Cory-Slechta (2000) Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: Environmental risk factors for Parkinson's disease? Brain Res. 873, 225-234.
79. Trojanowski JQ and VM Lee (1998) Aggregation of neurofilament and α-synuclein proteins in Lewy bodies: Implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch. Neurol. 55, 151-152.
80. Trojanowski JQ, M Goedert, T Iwatsubo and VM Lee (1998) Fatal attractions: Abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ. 5, 832-837.
81. Uversky VN, J Li and AL Fink (2001a) Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276, 44284-44296.
82. Uversky VN, J Li and AL Fink (2001b) Pesticides directly accelerate the rate of α-synuclein fibril formation: A possible factor in Parkinson's disease. FEBS Lett. 500, 105-108.
83. Widdowson PS, MJ Farnworth, MG Simpson and EA Lock (1996a) Influence of age on the passage of paraquat through the blood-brain barrier in rats: a distribution and pathological examination. Hum. Exp. Toxicol. 15, 231-236.
84. Widdowson PS, MJ Farnworth, R Upton and MG Simpson (1996b) No changes in behaviour, nigro-striatal system neurochemistry or neuronal cell death following toxic multiple oral paraquat administration to rats. Hum. Exp. Toxicol. 15, 583-591.
85. Yang L, RT Matthews, JB Schulz, T Klockgether, AW Liac, JC Martinou, JB Penney Jr, BT Hyman and MF Beal (1998) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J. Neurosci. 18, 8145-8152.
86. Yang W and AY Sun (1998) Paraquat-induced free radical reaction in mouse brain microsomes. Neurochem. Res. 23, 47-53.
87. Youdim MB, D Ben-Schachar and P Riederer (1993) The possible role of iron in the etiopathology of Parkinson's disease [published erratum appears in Mov. Disord. 1993 Apr; 8 (2):255]. Mov. Disord. 8, 1-12.